3/31/2024 0 Comments Topcat spironolactoneHowever, there is currently no medical therapy that has been shown to improve outcomes in HFpEF it is therefore especially important to consider which subgroups of patients with HFpEF might benefit from spironolactone. When the components of the primary outcome were considered individually, only hospitalization for heart failure was significantly reduced in the spironolactone group compared to the placebo group.īecause the primary endpoint was not met, all other analyses must be interpreted with caution. The study found that spironolactone did not significantly reduce the incidence of the primary outcome, which was a composite of death from cardiovascular causes, aborted cardiac arrest, and hospitalization for heart failure. Patients were enrolled if they had a history of hospitalization with management of heart failure or if they met brain natriuretic peptide (BNP) criteria. The multicenter, international Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial was designed to test whether spironolactone also improves outcomes in patients with heart failure with preserved ejection fraction (HFpEF). Study Rundown: Mineralocorticoid-receptor antagonists such as spironolactone have been shown to reduce mortality and hospitalizations in patients with heart failure with reduced ejection fraction.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |